Topics:
Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Indiana University • NCI-CCC Thoracic Tumor Board Question • SWOG
What is your preferred first line treatment option for a fit patient with non-squamous NSCLC who is PDL1 positive (1-49%) with no driver mutations?
Does the 2020 approval of Nivolumab and Ipilimumab for mNSCLC with PDL1 >1% impact your decision?
Answer from: Medical Oncologist at Academic Institution
This is a group of patients that often gets combination chemo-immunotherapy. However, during the pandemic, many institutions including my own treated patients on single agent immunotherapy (on the basis of the KN-042 study) to avoid chemotherapy-induced risks. My preference now is to discuss the INS...
Answer from: Medical Oncologist at Academic Institution
For chemo eligible patients, I still favor chemo-IO combination (KEYNOTE-189 regimen). This trial has the best data so far for PD-L1 (22c3) TPS: 1-49% (ORR ~ 49% Md DOR 12.9 mo, Md OS 21.8 months) (Gadgeel et al., PMID 32150489, Gandhi et al., PMID 29658856).
For chemo-ineligible patients, Nivo...
I would add that patients who recurred after durva...
Agree with @Shadia I. Jalal. I would use chemo-imm...